Legend Biotech Names Novartis Executive Ingrid Zhang as CEO
Event summary
- Ingrid Zhang appointed CEO of Legend Biotech effective September 15, 2026, succeeding interim CEO Alan Bash.
- Zhang previously served as Chief Commercial Officer at Novartis, with leadership roles at AstraZeneca, Pfizer, and McKinsey.
- Legend Biotech operates with 3,000 employees and markets CARVYKTI® in partnership with Johnson & Johnson.
- Alan Bash transitions back to President, CARVYKTI, after serving as interim CEO since July 2026.
The big picture
Legend Biotech’s appointment of Ingrid Zhang as CEO underscores its push for global commercial growth in the competitive cell therapy space. With CARVYKTI as its flagship product and a pipeline of innovative treatments, the company aims to solidify its position as a leader in cancer care. Zhang’s background in large-scale biopharmaceutical operations suggests a strategic focus on operational discipline and market expansion.
What we're watching
- Commercial Strategy
- How Zhang’s Novartis experience will shape Legend Biotech’s commercial expansion and pipeline advancement.
- Operational Execution
- Whether Zhang can sustain the momentum of CARVYKTI while driving future innovation across the pipeline.
- Global Expansion
- The pace at which Legend Biotech can scale its cell therapy leadership beyond its current U.S.-centered operations.
Related topics